Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

20141,944 citationsJournal Articlebronze Open Access

Authors

Stephen Salloway · Providence College

Reisa A. Sperling · Brigham and Women's Hospital

Nick C. Fox · University College London

Kaj Blennow · Sahlgrenska University Hospital

William E. Klunk · University of Pittsburgh

Murray A. Raskind · Veterans Health Administration

Marwan N. Sabbagh

Abstract

Bapineuzumab did not improve clinical outcomes in patients with Alzheimer's disease, despite treatment differences in biomarkers observed in APOE ε4 carriers. (Funded by Janssen Alzheimer Immunotherapy and Pfizer; Bapineuzumab 301 and 302 ClinicalTrials.gov numbers, NCT00575055 and NCT00574132, and EudraCT number, 2009-012748-17.).

Topics & Keywords

Alzheimer's disease research and treatments Dementia and Cognitive Impairment Research S100 Proteins and Annexins

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 370, Issue 4, pp. 322-333

DOI: 10.1056/nejmoa1304839

Field-Weighted Citation Impact: 123.85